Dr. Karim A. Touijer, MD

Dr. Touijer practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Touijer's NPI, 1932186376, was assigned on December 28, 2005. Dr. Touijer graduated from Hassan II University Faculty of Medicine in 1992. Dr. Touijer's New York license number on file is 225545-1.

Dr. Touijer's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Touijer's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Touijer to 2 more group practices and clinics and 1 medical group, each named with a free account. Dr. Touijer's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Touijer practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Touijer's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Touijer is board certified in urology by the American Board of Urology. Dmand AI has Dr. Touijer's licenses on file in 3 states: New York, Florida and Arkansas.

Dmand AI lists kidney cysts, prostate cancer, prostate surgery and urinary endoscopy among the conditions Dr. Touijer treats.

CMS data shows 606 Medicare services from Dr. Touijer across 12 procedure codes in 2024, for 351 Medicare patients. Medicare paid $102,453 for them. Every service was in an office.

CMS counts 351 Medicare patients who saw Dr. Touijer in 2024. The largest group is 65 to 74, with 215 patients. 75% of them have cancer, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Touijer's median patient age at 71, with 9% women.

In 2024, Dr. Touijer wrote 22 Medicare Part D claims. 86% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $176 in total drug cost. In 2021, CMS named 31 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Touijer for performance year 2024, reported as part of a group. Dr. Touijer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Touijer as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 192 papers to Dr. Touijer, published from 2005 to 2025. 2016 was the busiest year, with 18. The most frequent topics are Prostatic Neoplasms, Prostatectomy and Laparoscopy. Dr. Touijer has published most often in Eur Urol. Dr. Touijer's most frequent co-authors are James A. Eastham, MD, Vincent P. Laudone, MD and Jonathan Andrew Coleman, MD.

Dmand AI links Dr. Touijer to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 3 general payments to Dr. Touijer from 2 drug and device companies from 2024 to 2025. Travel and lodging make up the largest share, 49% of the total. Recordati_rare_diseases_inc. paid the most, $10,721.

Dr. Touijer graduated from Hassan II University Faculty of Medicine in 1992.

Dr. Touijer is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.